ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0373

Medical Cannabis in Ankylosing Spondylitis Following Recreational Legalization: A Prospective Cross-sectional Study

Emmanouil Rampakakis1, Yoram Shir2, John Sampalis1, Martin Cohen2, Michael Starr2, Winfried Häuser3 and Mary-Ann Fitzcharles2, 1JSS Medical Research, St-Laurent, QC, Canada, 2McGill university, montreal, Canada, 3Technische Universität München, Munich, Germany

Meeting: ACR Convergence 2020

Keywords: Ankylosing spondylitis (AS), pain, Therapy, alternative

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Friday, November 6, 2020

Title: Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster I

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Recreational legalization of cannabis has influenced the medical use by patients. When only legal medical access was available in Canada, 4.3% of all rheumatology patients reported medical use, with this number increasing to 12.6% following recreational legalization. In this study we examine the prevalence of medical cannabis use and explore factors associated with medical use in patients with ankylosing spondylitis (AS). 

Methods: During a two-month period (April-May 2019), consecutive patients attending an academic, community-based rheumatology clinic staffed by 3 rheumatologists participated in an onsite survey comprising 2 questionnaires: 1) demographic and disease information completed by the rheumatologist, 2) patient anonymous questionnaire of health status, cannabis use (recreational and/or medicinal) and characteristics of use.

Results: In a cohort of 1000 rheumatology attendees (73% females; mean age 64 ± 14 yrs), medical cannabis (MC) had ever been used by 12.6% (95% CI: 10.7%-14.8%) with half continuing use. Inflammatory arthritis was diagnosed in 621 (62%), with 72 (7.2%) diagnosed with AS. Characteristics of AS patients are shown in Table 1. Of the 72 AS patients, 17 (24%) had used MC (95% CI: 14.4-35.1), with 9 (53%) continuing medical use. Past and current recreational cannabis use for all AS patients was 31 (43.1%) and 8 (11.1%) respectively, with no difference in ever recreational rates for medical users. AS users vs. AS non users did not differ for demographic or employment data; there was a trend for users to have more concomitant FM  35.3% vs 12.7% (p=0.065), used significantly more medication types 2.4 vs. 1.2 (p< 0.001), used more opioids 23.5% vs. 5.5% (p=0.049), had a poorer patient global assessment 5.3 vs. 3.6 (p=0.022) and had more pain 6.5 vs 4.4 (p=0.015). Inhalation was the most common method of medical cannabis use. Symptom relief was 5.1±2.1 on a 10 cm VAS.

Conclusion: AS patients had double the rate of medical cannabis use compared to other rheumatology patients. Poorly controlled pain may be the driver for an increased MC in AS, although the effect was perceived as modest.

Table 1. Demographic and ankylosing spondylitis disease related information (part 1)

Table 1. Demographic and ankylosing spondylitis disease related information (part 2)

Table 1. Demographic and ankylosing spondylitis disease related information (part 3)


Disclosure: E. Rampakakis, None; Y. Shir, None; J. Sampalis, None; M. Cohen, None; M. Starr, None; W. Häuser, None; M. Fitzcharles, None.

To cite this abstract in AMA style:

Rampakakis E, Shir Y, Sampalis J, Cohen M, Starr M, Häuser W, Fitzcharles M. Medical Cannabis in Ankylosing Spondylitis Following Recreational Legalization: A Prospective Cross-sectional Study [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/medical-cannabis-in-ankylosing-spondylitis-following-recreational-legalization-a-prospective-cross-sectional-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/medical-cannabis-in-ankylosing-spondylitis-following-recreational-legalization-a-prospective-cross-sectional-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology